Transforming IVF so anyone can start a family
U-Ploid is developing a new class of reproductive therapeutics, starting with a treatment to improve egg quality for women in their mid-30s and above.
Our therapeutics are designed to integrate seamlessly into existing IVF procedures worldwide.
The chances of conceiving later in life, even with IVF, are reduced. But it doesn’t have to be that way. Reproductive healthcare should be empowering, effective and accessible.
In women under 35, 1 in 3 IVF cycles lead to pregnancy
In women over 40, it’s less than 1 in 20
At U-Ploid, we are developing innovative treatments to radically improve IVF outcomes for families around the world.
Reproductive healthcare needs innovation
Despite the surging demand for IVF, there have been no significant improvements in reproductive health outcomes for decades.
At U-Ploid, we’ve assembled an international team of leading scientists, embryologists, and industry leaders to bring the latest medical advances from the lab to the clinic.
Targeting the main barrier to IVF success
Our lead programme is a first in class therapeutic aimed at improving egg quality for women in their mid-30s and above by reducing the occurrence of meiotic aneuploidy: a condition where the egg transfers an incorrect number of chromosome copies to the embryo.
Meiotic aneuploidy arises in more than 50% of eggs from women aged 33 years and above – making it the major cause of IVF failure.
Our team of scientists are collaborating with leading clinics to develop cutting-edge treatments to improve reproductive health outcomes for families around the world.
News
EQT selects U-Ploid as a top 25 breakthrough company of 2025
EQT selects U-Ploid as a top 25 breakthrough company of 2025
Join us as we redefine the future of reproductive health.
We’re building the next generation of reproductive therapeutics, driven by science and compassion.
info@u-ploid.com – Collaborations & General
careers@u-ploid.com – Roles & Internships
press@u-ploid.com – Media
